[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
OBJECTIVE
In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely. But the chemosensitivity of individuals to various antitumor drugs is different. This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test.


METHODS
The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay.


RESULTS
The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX). Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively. Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%. Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter.


CONCLUSIONS
MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer. Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
Xiao
Yan
Y
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
Li
Jun-Dong
JD
Shi
Hong-Liu
HL
Liu
Ji-Hong
JH
Feng
Yan-Ling
YL
Li
Meng-Da
MD
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D016190:Carboplatin / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology*; D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000494:pharmacology; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology*
D000970:Antineoplastic Agents; D001761:Bleomycin; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil